EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 3.0

PEAR1, PON1, CYP2C19, CYP1A2 and F2R Polymorphisms are Associated with MACE in Clopidogrel-Treated Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention

Pengqiang Du iD, Xingang Li iD, Dandan Li, Yongcheng Ma, Ming Ni, Yafei Li, Wenbo Li, Aifeng Wang, Xiaowei Xu

Pharmacogenomics and Personalized Medicine · 2024-12 · Volume 17 · 611-621

DOI: 10.2147/pgpm.s490030 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmacogenomics and Personalized Medicine, 2024-12. Verfasst von Pengqiang Du und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Fuwai Central China Cardiovascular Hospital, Henan Provincial People's Hospital, Central China Fuwai Hospital of Zhengzhou Un…. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

Stichwörter der Autor:innen

MACEacute coronary syndromeclopidogrelpercutaneous coronary interventionsingle nucleotide polymorphism

Autor:innen und Institutionen

  • Department of Pharmacy, Fuwai Central China Cardiovascular Hospital, Henan Provincial People's Hospital, Central China Fuwai Hospital of Zhengzhou University, Zhengzhou, 450003, People's Republic of China.
  • Department of Pharmacy, Beijing Friendship Hospital, Capital Medical University, Beijing, 100050, People's Republic of China.
  • Department of Cardiology, Fuwai Central China Cardiovascular Hospital, Henan Provincial People's Hospital, Central China Fuwai Hospital of Zhengzhou University, Zhengzhou, 450003, People's Republic of China.
  • Department of Cardiology, Beijing Tiantan Hospital, Capital Medical University, Beijing, 100050, People's Republic of China.

ORCID-Profile: Pengqiang Du, Xingang Li

Zitieren

APA

Du, P., Li, X., Li, D., Ma, Y., Ni, M., Li, Y., Li, W., Wang, A., & Xu, X. (2024). PEAR1, PON1, CYP2C19, CYP1A2 and F2R Polymorphisms are Associated with MACE in Clopidogrel-Treated Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention. Pharmacogenomics and Personalized Medicine, Volume 17, 611-621. https://doi.org/10.2147/pgpm.s490030

Vancouver

Du P, Li X, Li D, Ma Y, Ni M, Li Y, et al. PEAR1, PON1, CYP2C19, CYP1A2 and F2R Polymorphisms are Associated with MACE in Clopidogrel-Treated Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention. Pharmacogenomics and Personalized Medicine. 2024;Volume 17:611-621. doi:10.2147/pgpm.s490030

BibTeX
@article{Du2024,
  author = {Du, Pengqiang and Li, Xingang and Li, Dandan and Ma, Yongcheng and Ni, Ming and Li, Yafei and Li, Wenbo and Wang, Aifeng and Xu, Xiaowei},
  title = {PEAR1, PON1, CYP2C19, CYP1A2 and F2R Polymorphisms are Associated with MACE in Clopidogrel-Treated Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention},
  journal = {Pharmacogenomics and Personalized Medicine},
  year = {2024},
  volume = {Volume 17},
  pages = {611--621},
  doi = {10.2147/pgpm.s490030}
}
Kostenlos starten →